Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Reporting Period: Fiscal year ended December 31, 2005
Business Overview: BioTime is a biomedical organization developing synthetic plasma expanders, blood volume substitutes, and organ preservation solutions. Its primary commercial product is Hextend, a plasma volume expander licensed to Hospira (North America), CJ Corp (South Korea), and Summit Pharmaceuticals (Japan, China, Taiwan). The company is also developing PentaLyte (plasma expander) and HetaCool (hypothermic blood substitute/organ preservative).
Key Financial Metrics
| Metric | 2005 | 2004 |
|---|---|---|
| Total Revenue | $903,200 | $688,377 |
| Net Loss | $(2,074,251) | $(3,085,324) |
| Loss Per Share (Basic/Diluted) | $(0.12) | $(0.18) |
| Cash and Cash Equivalents | $1,833,774 | $1,370,762 |
| Working Capital | $1,225,033 | $991,481 |
| Shareholders' Equity (Deficit) | $(196,581) | $344,770 |
| Research & Development Expenses | $1,525,686 | $1,123,261 |
| General & Administrative Expenses | $1,395,925 | $1,484,372 |
Revenue Composition (2005): Royalties from product sales ($626,135), License fees ($113,039), and Grant income ($164,026).
Debt: No debentures outstanding as of December 31, 2005 (retired in 2004). A $500,000 revolving line of credit was established in April 2006 (subsequent event), but no funds were drawn as of the filing date.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 31% to $903,200, driven by a 6% increase in royalties from Hextend sales and a significant increase in NIH grant income ($164,026 vs. $20,160 in 2004).
- Reduced Net Loss: Net loss decreased by approximately $1 million compared to 2004, primarily due to the elimination of significant interest expense associated with debenture retirement in 2004.
- Increased R&D Spend: R&D expenses rose 36% to $1.53 million, largely due to $379,326 in outside research costs for Phase II clinical trials of PentaLyte.
- Equity Position: The company moved from a positive shareholders' equity of $344,770 in 2004 to a deficit of $(196,581) in 2005, despite raising $1.79 million in a December 2005 rights offering.
Outlook, Risks, and Management Commentary
- Liquidity and Runway: Management projects that current cash, anticipated royalties, and the new line of credit will allow operations to continue through September 30, 2007. However, the company expects to incur losses in the near term and may need to raise additional capital, which could dilute shareholders.
- Product Development:
- Hextend: Sales to hospitals increased, offset by decreased sales to the U.S. Armed Forces.
- PentaLyte: Phase II clinical trials are ongoing. Management estimates an additional $370,000 is needed to complete the trial. Future Phase III costs are undetermined.
- HetaCool: Development continues with NIH grant funding for animal studies regarding hypothermic blood substitution and organ preservation.
- Risks:
- Capital Needs: Reliance on equity financing and licensing fees; inability to raise funds could force curtailment of R&D.
- Regulatory Approval: Future products (PentaLyte, HetaCool) require FDA approval, which is costly, time-consuming, and uncertain.
- Competition: Competes with lower-priced crystalloid solutions and albumin; generic 6% hetastarch solutions have faced FDA warnings, potentially benefiting Hextend.
- Key Personnel: The company operates under an "Office of the President" following the death of the CEO in 2003; no new CEO has been appointed due to cost constraints.
- Accounting Note: Payments received from Summit Pharmaceuticals ($900,000 total through 2005) are recorded as a "Royalty Obligation" (debt-like liability) under EITF 88-18 rather than immediate revenue, due to continuing performance obligations.
Investor Verification Checklist
- Cash Burn Rate: Verify if the projected runway through September 2007 holds given the current rate of R&D spending on PentaLyte trials.
- Summit Agreement Accounting: Confirm the treatment of the $770,000 "Royalty Obligation" and the impact of the 25.2% imputed interest rate on future earnings.
- Hextend Royalty Trends: Monitor quarterly royalty reports from Hospira to ensure sales growth is sustainable and not solely dependent on intermittent military orders.
- PentaLyte Trial Costs: Assess the risk that Phase II and subsequent Phase III trial costs may exceed the estimated $370,000, potentially requiring immediate capital raises.
- Stock Dilution: Review the terms of the 2005 Rights Offer and the April 2006 line of credit (which included issuance of 100,000 shares) to understand dilution impact on existing shareholders.